Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.73 |
| ▸ | GAA | P10253 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.44 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012527 | 1.00 | KDM4E (0.73) | KDM4EGAAPOLBALDH1A1HPGD | |
| SCHEMBL3470108 | 0.95 | KDM4E (0.65) | KDM4EGAAPOLBALDH1A1HPGD | |
| SCHEMBL13027979 | 0.89 | KDM4E (0.54) | KDM4EGAAPOLBALDH1A1HPGD | |
| SCHEMBL22056915 | 0.88 | KDM4E (0.73) | KDM4EGAAPOLBALDH1A1HPGD | |
| SCHEMBL14705178 | 0.88 | KDM4E (0.73) | KDM4EGAAPOLBALDH1A1HPGD | |
| SCHEMBL5500188 | 0.87 | KDM4E (0.55) | KDM4EGAAALDH1A1HPGDMAPT | |
| SCHEMBL14418089 | 0.87 | KDM4E (0.71) | KDM4EGAAPOLBALDH1A1HPGD | |
| SCHEMBL1011896 | 0.87 | KDM4E (0.71) | KDM4EGAAPOLBALDH1A1HPGD | |
| SCHEMBL1013016 | 0.87 | KDM4E (0.71) | KDM4EGAAPOLBALDH1A1HPGD | |
| SCHEMBL1011427 | 0.87 | KDM4E (0.71) | KDM4EGAAPOLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336606-A1 | SUBSTITUTED BENZO OR PYRIDOPYRIMIDINE AMINE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI ZELGEN PHARMA.TECH CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| EP-4234548-A1 | SUBSTITUTED BENZO OR PYRIDOPYRIMIDINE AMINE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234548-A1 | SUBSTITUTED BENZO OR PYRIDOPYRIMIDINE AMINE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2023-08-30 | — | — | EP | disclosed |
| CN-116323590-A | Substituted benzo or pyridopyrimidine amine inhibitor, preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115611865-A | Substituted benzo or pyrido pyrimidine amine inhibitor and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| WO-2022083657-A1 | SUBSTITUTED BENZO OR PYRIDOPYRIMIDINE AMINE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 苏州泽璟生物制药股份有限公司 | 2022-04-28 | — | — | WO | disclosed |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-9730937-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-2227460-B1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2011-05-19 | — | — | US | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2227460-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009053694-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053694-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | KDM4E 1824/4885GAA 2536/4885POLB 2074/4885 |
| US-20240336606-A1 | SUBSTITUTED BENZO OR PYRIDOPYRIMIDINE AMINE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, SOS1, WEE2 | KDM4E 3437/4885GAA 3234/4885POLB 2437/4885 |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | KDM4E 2179/4885GAA 2627/4885POLB 2867/4885 |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CHEK2, CHEK1, PLK1 | KDM4E 1238/4885GAA 737/4885POLB 96/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | KDM4E 1824/4885GAA 2536/4885POLB 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.